Imidazopyrimidines, Potent Inhibitors of P38 MAP Kinase
The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.
Montclair State University Digital Commons Citation
Rupert, Kenneth C.; Henry, James R.; Dodd, John H.; Wadsworth, Scott A.; Cavender, Druie E.; Olini, Gilbert C.; Fahmy, Bohumila; and Siekierka, John, "Imidazopyrimidines, Potent Inhibitors of P38 MAP Kinase" (2003). Department of Chemistry and Biochemistry Faculty Scholarship and Creative Works. 358.